?? T cells in cancer immunotherapy #MMPMID27823972
Zou C; Zhao P; Xiao Z; Han X; Fu F; Fu L
Oncotarget 2017[Jan]; 8 (5): 8900-9 PMID27823972show ga
?? T cells are one of the three immune cell types that express antigen receptors. They contribute to lymphoid antitumor surveillance and bridge the gap between innate and adaptive immunity. ?? T cells have the capacity of secreting abundant cytokines and exerting potent cytotoxicity against a wide range of cancer cells. ?? T cells exhibit important roles in immune-surveillance and immune defense against tumors and have become attractive effector cells for cancer immunotherapy. ?? T cells mediate anti-tumor therapy mainly by secreting pro-apoptotic molecules and inflammatory cytokines, or through a TCR-dependent pathway. Recently, ?? T cells are making their way into clinical trials. Some clinical trials demonstrated that ?? T cell-based immunotherapy is well tolerated and efficient. Despite the advantages that could be exploited, there are obstacles have to be addressed for the development of ?? T cell immunotherapies. Future direction for immunotherapy using ?? T cells should focus on overcoming the side effects of ?? T cells and exploring better antigens that help stimulating ?? T cell expansion in vitro.
free
free
free
Oncotarget 2017 ; 8 (5): 8900-9
